<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hanassab S</submitter><funding>European Research Council</funding><funding>National Institute for Health Research (NIHR)</funding><funding>Vodafone Foundation</funding><funding>National Institute for Health and Care Research</funding><funding>UK Research and Innovation</funding><funding>Engineering and Physical Sciences Research Council</funding><pagination>68</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12669042</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>3(1)</volume><pubmed_abstract>Polycystic ovary syndrome (PCOS) is a complex, multifactorial, and polygenic disorder. Here, we employed machine learning (ML) techniques to analyze large open-source datasets to identify bioactive molecules in foods and pharmacological agents that interact with genes and biological functions central to PCOS pathophysiology. We selected 13 PCOS-associated genes as targets, and the network propagation algorithm systematically identified bioactive molecules that interact with pathways relevant to PCOS. Among the top-ranked molecules, epicatechin-3-gallate (found in green tea) and 24-methylenecycloartan-3-ol (found in almonds) were newly identified, with green tea and almonds previously demonstrated to have anti-androgenic and anti-inflammatory properties. Validation of the ML pipeline with clinically available drugs revealed significant interactions with gonadotropin-releasing hormone receptor modulators, consistent with their established role in PCOS pathophysiology. These findings identify novel therapeutic targets for further research in precision nutrition and drug repurposing for PCOS treatment.</pubmed_abstract><journal>npj women's health</journal><pubmed_title>Identifying nutraceutical targets to treat polycystic ovary syndrome using graph representation learning.</pubmed_title><pmcid>PMC12669042</pmcid><funding_grant_id>NIHR304591</funding_grant_id><funding_grant_id>EP/X040062/1</funding_grant_id><funding_grant_id>EP/S023283/1</funding_grant_id><funding_grant_id>NIHR202371</funding_grant_id><funding_grant_id>CS-2018-18-ST2-002</funding_grant_id><funding_grant_id>899932</funding_grant_id><pubmed_authors>Laponogov I</pubmed_authors><pubmed_authors>Bronstein M</pubmed_authors><pubmed_authors>Hanassab S</pubmed_authors><pubmed_authors>Izzi-Engbeaya C</pubmed_authors><pubmed_authors>Dhillo WS</pubmed_authors><pubmed_authors>Olabode AV</pubmed_authors><pubmed_authors>Heinis T</pubmed_authors><pubmed_authors>Abbara A</pubmed_authors><pubmed_authors>Veselkov K</pubmed_authors><pubmed_authors>Southern J</pubmed_authors><pubmed_authors>Comninos AN</pubmed_authors></additional><is_claimable>false</is_claimable><name>Identifying nutraceutical targets to treat polycystic ovary syndrome using graph representation learning.</name><description>Polycystic ovary syndrome (PCOS) is a complex, multifactorial, and polygenic disorder. Here, we employed machine learning (ML) techniques to analyze large open-source datasets to identify bioactive molecules in foods and pharmacological agents that interact with genes and biological functions central to PCOS pathophysiology. We selected 13 PCOS-associated genes as targets, and the network propagation algorithm systematically identified bioactive molecules that interact with pathways relevant to PCOS. Among the top-ranked molecules, epicatechin-3-gallate (found in green tea) and 24-methylenecycloartan-3-ol (found in almonds) were newly identified, with green tea and almonds previously demonstrated to have anti-androgenic and anti-inflammatory properties. Validation of the ML pipeline with clinically available drugs revealed significant interactions with gonadotropin-releasing hormone receptor modulators, consistent with their established role in PCOS pathophysiology. These findings identify novel therapeutic targets for further research in precision nutrition and drug repurposing for PCOS treatment.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-06-25T03:11:42.284Z</modification><creation>2026-06-25T03:07:38.99Z</creation></dates><accession>S-EPMC12669042</accession><cross_references><pubmed>41341431</pubmed><doi>10.1038/s44294-025-00117-4</doi></cross_references></HashMap>